Kevin came to the U.S. from Fier, Albania to pursue his undergraduate education, graduating summa cum laude with a B.S. in Biology and minor in Physics from Tufts University in 2017. After graduation, Kevin worked as a research associate in the Jacks Lab at the Koch Institute for Integrative Cancer Research at MIT, where he investigated epigenetic mechanisms of lung adenocarcinoma progression in a genetically engineered mouse model.
Kevin is a 3rd-year Ph.D. candidate in Biological and Biomedical Sciences at Harvard University, and holds an appointment at the Dana-Farber Cancer Institute, where he is a member of the Van Allen Lab. He is currently working on a project investigating endogenous retroviruses and response to immunotherapy in melanoma and renal cell carcinoma.
Outside of lab, Kevin is a member of the Harvard Biotech Club, where he serves as the Director of Biotechnology Investment Course.
Kevin is a 3rd-year Ph.D. candidate in Biological and Biomedical Sciences at Harvard University, and holds an appointment at the Dana-Farber Cancer Institute, where he is a member of the Van Allen Lab. He is currently working on a project investigating endogenous retroviruses and response to immunotherapy in melanoma and renal cell carcinoma.
Outside of lab, Kevin is a member of the Harvard Biotech Club, where he serves as the Director of Biotechnology Investment Course.
